The De Ritis Ratio (AST/ALT) and Its Diagnostic Relevance in ISUP Grade Reclassification After Prostatectomy
Abstract
Aim: The prognostic value of the De Ritis ratio (AST/ALT) in localized prostate cancer remains uncertain. This study evaluated its predictive role in International Society of Urological Pathology (ISUP) grade upgrading and adverse pathological features following radical prostatectomy.
Material and Methods: This retrospective study included 152 patients who underwent radical prostatectomy for prostate adenocarcinoma between 2012 and 2022. The De Ritis ratio was calculated using preoperative AST and ALT levels. Patients were grouped according to ISUP grade upgrading between biopsy and final pathology. Receiver operating characteristic (ROC) analysis and multivariate logistic regression were performed.
Results: ISUP upgrading occurred in 46.3% of patients. Mean De Ritis ratios did not differ significantly between groups (p = 0.38). However, a ratio ≤1.22 was associated with higher upgrading rates (51.5% vs. 34.7%, p = 0.05). ROC analysis demonstrated limited discriminatory ability (AUC = 0.552; sensitivity 75%, specificity 39%). Multivariate analysis identified age (p = 0.02), prostate volume (p = 0.048), and biopsy ISUP grade (p = 0.001) as independent predictors, whereas the De Ritis ratio was not independently associated with upgrading.
Conclusions: The De Ritis ratio was not an independent predictor of ISUP upgrading, although associations with adverse pathological features were observed. Its limited discriminatory performance suggests that it should not be used as a standalone predictor. Further prospective studies are warranted to clarify its potential supplementary clinical value.
Keywords
References
- Cao J. Effect of immune checkpoint inhibitors on advanced prostate cancer: a meta-analysis. Arch Esp Urol. 2025;78(2):194-206. doi:10.56434/j.arch.esp.urol.20257802.27.
- Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730. doi:10.3390/molecules27175730.
- Morote J, Paesano N, Picola N, Muñoz-Rodriguez J, Ruiz-Plazas X, Muñoz-Rivero MV, et al. The role of digital rectal examination for early detection of significant prostate cancer in the era of magnetic resonance imaging. Life (Basel). 2024;14(11):1359. doi:10.3390/life14111359.
- Bujaldon JM, Vitagliano GJ, Blas L, Vocos MM, Pita HR. Freehand transperineal prostate biopsy improves the detection rate of clinically significant prostate cancer. Urol Res Pract. 2025;50(5):269. doi:10.5152/tud.2025.24026.
- De Ritis F, Mallucci L, Coltorti M, Giusti G, Caldera M. Anicteric virus hepatitis in a closed environment as shown by serum transaminase activity. Bull World Health Organ. 1959;20(4):589-602.
- Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal transduction and targeted therapy. 2024;9(1):132. doi:10.1038/s41392-024-01823-2.
- Nazari M, Babakhanzadeh E, Mollazadeh A, Ahmadzade M, Mohammadi Soleimani E, Hajimaqsoudi E. HOTAIR in cancer: Diagnostic, prognostic, and therapeutic perspectives. Cancer Cell Int. 2024;24(1):415. doi:10.1186/s12935-024-03612-x.
- Chen W, Wang W, Zhou L, Zhou J, He L, Li J, et al. Elevated AST/ALT ratio is associated with all‐cause mortality and cancer incident. Journal of clinical laboratory analysis. 2022;36(5):e24356. doi:10.1002/jcla.24356.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Publication Date
October 27, 2026
Submission Date
February 18, 2026
Acceptance Date
August 10, 2026
Published in Issue
Year 2026 Volume: 18 Number: 3
